CLINUVEL completes development of ZEROKIN™ proprietary drug delivery device
CLINUVEL Pharmaceuticals has completed the development of ZEROKIN™, a proprietary single-use administration device to administer controlled-release formulations developed through VALLAURIX, its Research, Development and Innovation Center in Singapore. The announcement, made on 8 September 2026, outlines four key milestones:
- Development of ZEROKIN™ completed
- IP application submitted
- Commercial manufacturer to be appointed
- FDA 510(k) dossier to be submitted (Class II device)
When big ASX news breaks, our subscribers know first
What is ZEROKIN™ and why does it matter?
A device built around patient and physician feedback
ZEROKIN™ is a disposable, single-use device designed for subcutaneous or intradermal administration of controlled-release formulations. Subcutaneous delivery refers to injections administered just beneath the skin, while controlled-release formulations are drug preparations engineered to release their active ingredient gradually over time rather than all at once.
The device is intended for both hospital use and self-administration, depending on the medication. According to the announcement, few commercially available devices are currently registered for subcutaneous or intradermal formulation delivery, a gap CLINUVEL identified and sought to address through purpose-built engineering.
VALLAURIX is developing a range of formulation approaches focused on the controlled-release delivery of peptides, with an initial focus on melanocortins. Melanocortins are a family of peptides that includes afamelanotide, the active ingredient in CLINUVEL’s approved therapy SCENESSE®.
The regulatory pathway for ZEROKIN™
ZEROKIN™ is intended as a Class II medical device. The regulatory steps outlined in the announcement are:
- IP application submitted
- Commercial manufacturer to be appointed
- FDA 510(k) dossier to be submitted
- CE marking application under EU Medical Device Regulations
The 510(k) pathway is a well-established FDA clearance route for Class II devices, meaning this is not a novel or untested regulatory approach for the company to navigate.
CLINUVEL’s FDA regulatory track record adds context to the 510(k) filing plan: earlier in 2026 the agency removed a postmarketing cardiac study requirement for SCENESSE, citing accumulated long-term safety data, a signal of the pharmacovigilance discipline that typically supports smoother device clearance interactions.
A US$27.1 billion market opportunity in self-administered delivery
The global market for self-administered devices is projected to grow from US$27.1 billion in 2026 to US$40.5 billion by 2030. North America currently holds a dominant position, accounting for a revenue share of 42.4% in 2024.
The demand driver underpinning this growth is the rising prevalence of chronic conditions alongside the expanding availability of new classes of injectable therapeutics and peptides. The broader therapeutics and peptides market is projected to reach US$133.2 billion by 2030, amplifying the addressable opportunity for delivery infrastructure that can serve these products.
ZEROKIN™ positions CLINUVEL at the intersection of both markets: the growing self-administration device segment and the expanding peptide therapeutics sector.
| Market Segment | 2026 Value | 2030 Projection | Key Driver | CLINUVEL Relevance |
|---|---|---|---|---|
| Self-administered injection devices (global) | US$27.1B | US$40.5B | Chronic conditions; new injectable therapeutics | ZEROKIN™ targets this segment directly |
| Therapeutics and peptides (global) | Not stated | US$133.2B | New peptide drug classes; rising chronic disease burden | VALLAURIX melanocortin formulations |
| North America (device market share) | 42.4% (2024 revenue share) | Not stated | Established self-administration infrastructure | FDA 510(k) filing planned |
Strategic fit within CLINUVEL’s pipeline
From SCENESSE® learnings to next-generation delivery
Dr Dennis Wright, Chief Scientific Officer
“In parallel to our clinical development programs, our scientific teams have taken extensive feedback on the use of our drug SCENESSE® and other peptides in the clinic to try and anticipate how these products could better serve patient and physician needs… The bespoke ZEROKIN™ device is the direct result of this process, which we will now fast track to finished manufacture and regulatory filing. It is an important step forward alongside our formulation work in Singapore.”
ZEROKIN™ emerged directly from clinical experience with SCENESSE® and other peptide therapies, with the device purpose-built to address practical needs identified by patients and physicians. For investors, this signals that CLINUVEL is developing proprietary delivery infrastructure, not solely drug compounds, which could support multiple future formulations from the VALLAURIX pipeline.
VALLAURIX’s formulation work remains focused on controlled-release delivery of peptides, with melanocortins as the initial priority.
The VLRX-L peptide formulation selected from pre-clinical screening at VALLAURIX is designed to enable flexible, titrated dosing of melanocortin peptides, targeting patient populations beyond the existing SCENESSE indication, including adolescents and paediatric patients.
Next steps — what investors should watch
The announcement does not disclose specific timelines for the milestones below, but the following forward steps are outlined:
- Appointment of a commercial manufacturer
- Submission of the FDA 510(k) dossier
- CE marking application under EU Medical Device Regulations
- Progress of the VALLAURIX controlled-release peptide formulation pipeline
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to start receiving real-time coverage today.